Overview
RNA market data
Price History
RNA price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.89 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.00 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $11.36 – $73.06 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $196.5 · P/B 0.76 · P/S 5.14.
Company News
8-K filing — Atrium Therapeutics, Inc. (RNA)SEC EDGAR · Jul 14, 2026, 9:14 PM
Atrium Therapeutics Says FDA Clears IND Application Allowing It To Move Forward With Corventis Phase 1/2 Clinical Trial To Evaluate ATR 1072 For Treatment Of PRKAG2 SyndromeBenzinga · Jul 14, 2026, 10:33 AM
Cantor Fitzgerald Initiates Coverage On Atrium Therapeutics with Overweight Rating, Announces Price Target of $25Benzinga · Jun 18, 2026, 12:55 PM
Leerink Partners Initiates Coverage On Atrium Therapeutics with Outperform Rating, Announces Price Target of $25Benzinga · May 15, 2026, 5:34 PM
Atrium Therapeutics Q1 EPS $(0.97) Beats $(1.10) Estimate, Sales $19.635M Beat $2.000M EstimateBenzinga · May 14, 2026, 8:47 PM